HRP20120738T1 - Inhibitori kinaza akt i p70 s6 - Google Patents
Inhibitori kinaza akt i p70 s6 Download PDFInfo
- Publication number
- HRP20120738T1 HRP20120738T1 HRP20120738AT HRP20120738T HRP20120738T1 HR P20120738 T1 HRP20120738 T1 HR P20120738T1 HR P20120738A T HRP20120738A T HR P20120738AT HR P20120738 T HRP20120738 T HR P20120738T HR P20120738 T1 HRP20120738 T1 HR P20120738T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- attached
- independently
- Prior art date
Links
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- -1 2-thiazolyl Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims 2
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- YDFKZIGAUIKZGP-UHFFFAOYSA-N 4-[4-[1-[2-(dimethylamino)ethyl]-4-[4-fluoro-3-(trifluoromethyl)phenyl]imidazol-2-yl]piperidin-1-yl]-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(C2CCN(CC2)C=2C=3CC(=O)NC=3N=CN=2)N(CCN(C)C)C=C1C1=CC=C(F)C(C(F)(F)F)=C1 YDFKZIGAUIKZGP-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Spoj formule:
[image]
naznačen time što:
X je F, Cl, CF3, CN ili H;
Y je F, H ili Cl;
R1 i R2 su neovisno H, C1-C4 alkil ili CH2CH2OH; ili R1 i R2, zajedno s atomom dušika na kojeg su vezani, tvore pirolidinski prsten, izborno supstituiran s hidroksimetilom na položaju 2 ili s hidroksi na položaju 3, ili azetidinski prsten, supstituiran s hidroksi na položaju 3;
R3 je H ili OH;
R6 je H; ili R6 i R2, zajedno s atomom dušika na kojeg je R2 vezan, tvore piperidinski prsten;
R7 i R8 su neovisno H ili CH3; ili R7 i R1, zajedno s atomom dušika na kojeg je R1 vezan, tvore pirolidinski prsten;
W je CR4R5, NR10, C=O ili C=CH-R9;
R4 i R5 su neovisno H, CH3 ili CH2CH3; R4 i R5, zajedno s atomom ugljika na kojeg su vezani, tvore ciklopentanski prsten; ili jedan od R4 ili R5 je benzil, a drugi je H;
R9 je 2-tiazolil, 4-piridil, 2-metil-4-tiazolil, 2-imidazolil, 5-tiazolil ili 4-imidazolil; i
R10 je H ili C1-C3 alkil; ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što Y je F.
3. Spoj u skladu s patentnim zahtjevom 1 ili claim 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što X je Cl, CF3 ili F.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što W je CR4R5.
5. Spoj u skladu s patentnim zahtjevom 4, ili njegova farmaceutski prihvatljiva sol, naznačen time što su R4 i R5 neovisno H ili CH3, ili R4 i R5, zajedno s atomom ugljika na kojeg su vezani, tvore ciklopentanski prsten.
6. Spoju skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što W je NR10.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što W je C=CH-R9.
8. Spoj u skladu s patentnim zahtjevom 7, ili njegova farmaceutski prihvatljiva sol, naznačen time što R9 je 5-tiazolil.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, naznačen time što su R1 i R2 neovisno H, C1-C4 alkil ili CH2CH2OH; ili R1 i R2, zajedno s atomom dušika na kojeg su vezani, tvore pirolidinski prsten, izborno supstituiran s hidroksimetilom na položaju 2 ili s hidroksi na položaju 3.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, naznačen time što R3 je H.
11. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 4-{4-[1-(2-dimetilaminoetil)-4-(4-fluor-3-trifluormetilphenil)-1H-imidazol-2-il]piperidin-1-il}-5,7-dihidropirolo[2,3-d]pirimidin-6-on, ili njegova farmaceutski prihvatljiva sol.
12. Farmaceutska formulacija, naznačena time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
13. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju multiformnog glioblastoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11327308P | 2008-11-11 | 2008-11-11 | |
| PCT/US2009/063020 WO2010056563A1 (en) | 2008-11-11 | 2009-11-03 | Akt and p70 s6 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120738T1 true HRP20120738T1 (hr) | 2012-10-31 |
Family
ID=41402451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120738AT HRP20120738T1 (hr) | 2008-11-11 | 2012-09-17 | Inhibitori kinaza akt i p70 s6 |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US8148387B2 (hr) |
| EP (1) | EP2358710B1 (hr) |
| JP (1) | JP5432275B2 (hr) |
| KR (1) | KR101334460B1 (hr) |
| CN (1) | CN102216302B (hr) |
| AR (1) | AR074072A1 (hr) |
| AU (1) | AU2009314324B2 (hr) |
| BR (1) | BRPI0921916A2 (hr) |
| CA (1) | CA2743019C (hr) |
| CO (1) | CO6382114A2 (hr) |
| CR (1) | CR20110240A (hr) |
| CY (1) | CY1113409T1 (hr) |
| DK (1) | DK2358710T3 (hr) |
| DO (1) | DOP2011000129A (hr) |
| EA (1) | EA018947B1 (hr) |
| EC (1) | ECSP11011048A (hr) |
| ES (1) | ES2391704T3 (hr) |
| HK (1) | HK1158203A1 (hr) |
| HN (1) | HN2011001247A (hr) |
| HR (1) | HRP20120738T1 (hr) |
| IL (1) | IL211940A (hr) |
| JO (1) | JO2822B1 (hr) |
| MA (1) | MA32776B1 (hr) |
| MX (1) | MX2011005000A (hr) |
| MY (1) | MY161461A (hr) |
| NZ (1) | NZ592062A (hr) |
| PA (1) | PA8846901A1 (hr) |
| PE (1) | PE20110807A1 (hr) |
| PL (1) | PL2358710T3 (hr) |
| PT (1) | PT2358710E (hr) |
| RS (1) | RS52520B (hr) |
| SI (1) | SI2358710T1 (hr) |
| TN (1) | TN2011000207A1 (hr) |
| TW (1) | TWI422587B (hr) |
| UA (1) | UA100190C2 (hr) |
| WO (1) | WO2010056563A1 (hr) |
| ZA (1) | ZA201102549B (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120640A1 (es) | 2009-07-02 | 2012-06-09 | Sanofi Sa | Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb) |
| CA2778291C (en) * | 2009-10-23 | 2014-02-11 | Eli Lilly And Company | Akt inhibitors |
| HUE026323T2 (en) | 2011-04-07 | 2016-05-30 | Bayer Ip Gmbh | Imidazopyridazines as AKT kinase inhibitors |
| US8927572B2 (en) * | 2011-07-09 | 2015-01-06 | Xuanzhu Pharma Co., Ltd. | Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof |
| US9321760B2 (en) | 2011-09-12 | 2016-04-26 | Merck Patent Gmbh | Aminopyrimidine derivatives for use as modulators of kinase activity |
| PT2755965T (pt) * | 2011-09-12 | 2017-11-02 | Merck Patent Gmbh | Novas imidazol aminas como moduladores da atividade quinase |
| ES2656096T3 (es) | 2012-11-16 | 2018-02-23 | Merck Patent Gmbh | Nuevos derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa |
| WO2014078637A1 (en) | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | Novel heterocyclic derivatives as modulators of kinase activity |
| AR095202A1 (es) | 2013-03-11 | 2015-09-30 | Merck Patent Gmbh | Heterociclos como moduladores de la actividad quinasa |
| AU2015217397B2 (en) * | 2014-02-11 | 2019-01-17 | Merck Patent Gmbh | Pyrimidine imidazole amines as modulators of kinase activity |
| TW201718574A (zh) | 2015-08-12 | 2017-06-01 | 美國禮來大藥廠 | Ｃｇｒｐ受體拮抗劑 |
| ES2882018T3 (es) * | 2016-05-20 | 2021-11-30 | Taiho Pharmaceutical Co Ltd | Nuevo derivado de 5H-pirrolo[2,3-d]pirimidin-6(7H)-ona |
| BR112022017856A2 (pt) | 2020-03-17 | 2022-11-01 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Derivado bicíclico fundido, método de preparação do mesmo e uso farmacêutico do mesmo |
| CN113444110B (zh) * | 2020-03-25 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用 |
| EP4403550A1 (en) | 2021-09-17 | 2024-07-24 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused bicyclic derivative, pharmaceutically acceptable salt, crystal form thereof and preparation method therefor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1750727A2 (en) | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| EP1848719B1 (en) | 2004-12-28 | 2012-02-01 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| WO2006091450A1 (en) * | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
| WO2007003960A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| ES2878130T3 (es) | 2006-04-25 | 2021-11-18 | Astex Therapeutics Ltd | Derivados de purina y deazapurina como compuestos farmacéuticos |
| US20090082370A1 (en) | 2006-04-25 | 2009-03-26 | Neil Thomas Thompson | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
-
2009
- 2009-10-28 AR ARP090104158A patent/AR074072A1/es unknown
- 2009-10-29 JO JO2009400A patent/JO2822B1/en active
- 2009-10-29 PA PA20098846901A patent/PA8846901A1/es unknown
- 2009-10-29 TW TW098136731A patent/TWI422587B/zh not_active IP Right Cessation
- 2009-11-03 NZ NZ592062A patent/NZ592062A/xx not_active IP Right Cessation
- 2009-11-03 US US12/611,139 patent/US8148387B2/en active Active
- 2009-11-03 MY MYPI2011002030A patent/MY161461A/en unknown
- 2009-11-03 AU AU2009314324A patent/AU2009314324B2/en not_active Ceased
- 2009-11-03 DK DK09744896.3T patent/DK2358710T3/da active
- 2009-11-03 PE PE2011001018A patent/PE20110807A1/es not_active Application Discontinuation
- 2009-11-03 CA CA2743019A patent/CA2743019C/en not_active Expired - Fee Related
- 2009-11-03 WO PCT/US2009/063020 patent/WO2010056563A1/en active Application Filing
- 2009-11-03 KR KR1020117010569A patent/KR101334460B1/ko not_active IP Right Cessation
- 2009-11-03 CN CN2009801449532A patent/CN102216302B/zh active Active
- 2009-11-03 PL PL09744896T patent/PL2358710T3/pl unknown
- 2009-11-03 JP JP2011536383A patent/JP5432275B2/ja active Active
- 2009-11-03 EP EP09744896A patent/EP2358710B1/en active Active
- 2009-11-03 PT PT09744896T patent/PT2358710E/pt unknown
- 2009-11-03 RS RS20120443A patent/RS52520B/en unknown
- 2009-11-03 EA EA201170680A patent/EA018947B1/ru not_active IP Right Cessation
- 2009-11-03 UA UAA201105367A patent/UA100190C2/ru unknown
- 2009-11-03 SI SI200930348T patent/SI2358710T1/sl unknown
- 2009-11-03 ES ES09744896T patent/ES2391704T3/es active Active
- 2009-11-03 BR BRPI0921916A patent/BRPI0921916A2/pt not_active IP Right Cessation
- 2009-11-03 MX MX2011005000A patent/MX2011005000A/es active IP Right Grant
-
2011
- 2011-03-24 IL IL211940A patent/IL211940A/en not_active IP Right Cessation
- 2011-04-06 ZA ZA2011/02549A patent/ZA201102549B/en unknown
- 2011-04-25 TN TN2011000207A patent/TN2011000207A1/fr unknown
- 2011-05-03 HN HN2011001247A patent/HN2011001247A/es unknown
- 2011-05-06 CR CR20110240A patent/CR20110240A/es unknown
- 2011-05-09 MA MA33822A patent/MA32776B1/fr unknown
- 2011-05-09 DO DO2011000129A patent/DOP2011000129A/es unknown
- 2011-05-11 EC EC2011011048A patent/ECSP11011048A/es unknown
- 2011-05-12 CO CO11058555A patent/CO6382114A2/es active IP Right Grant
- 2011-11-24 HK HK11112734.3A patent/HK1158203A1/xx not_active IP Right Cessation
-
2012
- 2012-09-17 HR HRP20120738AT patent/HRP20120738T1/hr unknown
- 2012-10-05 CY CY20121100928T patent/CY1113409T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120738T1 (hr) | Inhibitori kinaza akt i p70 s6 | |
| RU2475487C2 (ru) | Имидазохинолины с иммуномодулирующими свойствами | |
| NZ595829A (en) | 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives | |
| JP2012508274A5 (hr) | ||
| TW200716645A (en) | Macrocyclic heterocyclic aspartyl protease inhibitors | |
| NZ602141A (en) | Inhibitors of semicarabazide-sensitive amine oxidase | |
| HRP20201107T1 (hr) | Heteroaril amidi kao inhibitori proteinske agregacije | |
| MX2009004441A (es) | Derivados de indazol utiles como inhibidores de las isoformas de higado. | |
| NO20083114L (no) | Polysykliske indazolderivater som er ERK-inhibitorer | |
| NZ594597A (en) | Substituted piperidines as ccr3 antagonists | |
| NI200600262A (es) | 4-fenilamino-quinazolin-6-il-amidas. | |
| PE20091201A1 (es) | AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) | |
| MX2010005824A (es) | Derivados de aminotiazol. | |
| NZ603364A (en) | Inhibitors of arginase and their therapeutic applications | |
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| TW200745032A (en) | Novel heterobicyclic derivatives | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
| NO20091548L (no) | Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes | |
| TN2011000611A1 (en) | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 | |
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
| PE20090887A1 (es) | DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6 | |
| RU2008105304A (ru) | Соединение бензоимидазола, способное к ингибированию простагландин-d-синтетазы | |
| MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
| JO2972B1 (en) | Piperidine / piperazine derivatives |